Alano M A, Ngougmna E, Ostrea E M, Konduri G G
Department of Pediatrics, Hutzel Hospital, Wayne State University, Detroit, Michigan 48201, USA.
Pediatrics. 2001 Mar;107(3):519-23. doi: 10.1542/peds.107.3.519.
The objective of this study was to detect fetal exposure to nonsteroidal antiinflammatory drugs (NSAIDs) by meconium analysis and to determine the relationship between fetal exposure to NSAIDs and the development of persistent pulmonary hypertension of the newborn (PPHN).
In a case-control study of the inborn and outborn nurseries of a large urban medical center, meconium was collected from 101 newborn infants (40 with the diagnosis of PPHN based on clinical or echocardiographic criteria and 61 randomly selected, healthy, term infants [control]) and analyzed for NSAIDs (ibuprofen, naproxen, indomethacin, and aspirin) by gas chromatography/mass spectrometry. The risk of developing PPHN was determined in infants who were exposed antenatally to NSAID.
Infants with PPHN (n = 40) had a mean gestation of 38.9 weeks and birth weight of 3524 g, which were similar to the those of the control group (n = 61). However, the incidence of low Apgar scores (</=6) at 1 minute and 5 minutes was significantly higher in the PPHN group than in the control group. The diagnoses associated with PPHN were primary PPHN (25%), meconium aspiration syndrome (35%), respiratory distress syndrome (20%), low Apgar score/asphyxia (12.5%), and pneumonia/sepsis (8%). Mean duration of ventilator support for the PPHN group was 11 days. Nitric oxide (NO) was given to 19 infants (47.5%) for a mean duration of 25.4 hours. Fourteen of the 19 infants who were treated with NO (74%) required extracorporeal membrane oxygenation, and 2 died. The overall incidence of positive NSAID in meconium in the study population (n = 101) was 49.5%: 22.8% were positive for ibuprofen, 18.8% for naproxen, 7.9% for indomethacin, and 43.6% for aspirin. There was poor agreement (Cohen's kappa = 0.09) between maternal history of NSAID use and NSAID detection in meconium. PPHN was significantly associated with 1) the presence of at least 1 NSAID in meconium (odds ratio [OR] = 21.47; 95% confidence interval [CI] = 7.12-64.71) or 2) the presence in meconium of aspirin (OR = 8.09; 95% CI = 3.27-20.10), ibuprofen (OR = 12.89; 95% CI 3.93-42.32), or naproxen (OR = 3.31; 95% CI = 1.17-9.33). By logistic regression analysis, low Apgar scores at 1 and 5 minutes and the antenatal exposure to aspirin, naproxen, and ibuprofen were significantly associated with PPHN and treatment with inhaled NO or extracorporeal membrane oxygenation.
We confirm by meconium analysis the results of previous studies that demonstrated that the use of NSAIDs during pregnancy, particularly aspirin, ibuprofen, and naproxen, is high; is grossly underestimated by maternal history; and is significantly associated with PPHN. Thus, the easy access to over-the-counter NSAIDs of pregnant women should be reevaluated, and the potential dangers of these drugs to the newborn infant should be more effectively promoted.
本研究的目的是通过胎粪分析检测胎儿暴露于非甾体抗炎药(NSAIDs)的情况,并确定胎儿暴露于NSAIDs与新生儿持续性肺动脉高压(PPHN)发生之间的关系。
在一家大型城市医疗中心的住院和非住院新生儿重症监护室进行病例对照研究,收集了101例新生儿的胎粪(40例根据临床或超声心动图标准诊断为PPHN,61例为随机选取的健康足月儿[对照组]),并通过气相色谱/质谱法分析其中的NSAIDs(布洛芬、萘普生、吲哚美辛和阿司匹林)。确定产前暴露于NSAIDs的婴儿发生PPHN的风险。
PPHN组婴儿(n = 40)的平均孕周为38.9周,出生体重为3524 g,与对照组(n = 61)相似。然而,PPHN组1分钟和5分钟时低Apgar评分(≤6)的发生率显著高于对照组。与PPHN相关的诊断包括原发性PPHN(25%)、胎粪吸入综合征(35%)、呼吸窘迫综合征(20%)、低Apgar评分/窒息(12.5%)以及肺炎/败血症(8%)。PPHN组机械通气支持的平均时间为11天。19例婴儿(47.5%)接受了一氧化氮(NO)治疗,平均治疗时间为25.4小时。接受NO治疗的19例婴儿中有14例(74%)需要体外膜肺氧合治疗,2例死亡。研究人群(n = 101)中胎粪NSAIDs阳性的总体发生率为49.5%:布洛芬阳性率为22.8%,萘普生为18.8%,吲哚美辛为7.9%,阿司匹林为43.6%。母亲NSAIDs使用史与胎粪中NSAIDs检测结果之间的一致性较差(Cohen's kappa = 0.09)。PPHN与以下因素显著相关:1)胎粪中至少存在1种NSAIDs(比值比[OR] = 21.47;95%置信区间[CI] = 7.12 - 64.71),或2)胎粪中存在阿司匹林(OR = 8.09;95% CI = 3.27 - 20.10)、布洛芬(OR = 12.89;95% CI 3.93 - 42.32)或萘普生(OR = 3.31;95% CI = 1.17 - 9.33)。通过逻辑回归分析,1分钟和5分钟时的低Apgar评分以及产前暴露于阿司匹林、萘普生和布洛芬与PPHN以及吸入NO或体外膜肺氧合治疗显著相关。
我们通过胎粪分析证实了先前研究的结果,即孕期使用NSAIDs,尤其是阿司匹林、布洛芬和萘普生的情况很常见;母亲的用药史严重低估了这一情况;且与PPHN显著相关。因此,应重新评估孕妇获取非处方NSAIDs的便利性,并更有效地宣传这些药物对新生儿的潜在危害。